

1 ***Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal***
2 ***insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and***
3 ***meta-analysis of randomized clinical trials***
4

5 Mansur A. Ramalan^{1*}

6 Musa Baba Maiyaki^{1,2,3}

7 Ibrahim D Gezawa^{1,2},

8 Andrew E Uloko^{1,2},

9 ¹ Department of Internal Medicine, Aminu Kano Teaching Hospital, Kano, Kano State,
10 Nigeria

11 ² Department of Internal Medicine, Bayero University, Kano, Kano State, Nigeria

12 ³ Africa Center of Excellence for Population Health and Policy Bayero University Kano, Kano
13 State, Nigeria

14 * Corresponding author

15 E-mail: mmramalan@gmail.com (MAR)

16

17 **Author contribution**
18

19 **Mansur Aliyu Ramalan**, Conceptualization, Methodology, Project administration, Writing –
20 original draft, Writing – review & editing, **Ibrahim D Gezawa**, Writing – original draft, Writing
21 – review & editing, **Andrew Uloko** Writing – original draft, Writing – review & editing, **Musa**
22 **Babamaiyaki**, Methodology, Writing – review & editing

23 Prospero registration number CRD42022363619

24

25

26

27

28

29

30 **Abstract**

31 **Background**

32 Blood glucose control is a major goal of management demonstrated by many guidelines and
33 results of clinical trials. Achieving good glycaemia is associated with reduction of the risks of
34 cardiovascular disease. Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are now
35 important parts of many guidelines for the management of diabetes mellitus because of their
36 cardiovascular benefit. Basal insulin in have now been combined with GLP-1 RAs in fixed
37 ration combinations in single pens. We aim to conduct a meta-analysis and systematic review
38 of randomized control clinical trials the evaluate the therapeutic efficacy of glucagon-like
39 peptide-1 receptor agonists combined with basal insulin therapy in treating type 2 diabetes,
40 using a fixed-ratio combination of the two.

41 **Method and data analysis**

42 It is anticipated that a systematic search of the literature will be conducted on the following
43 electronic databases will be searched: The Cochrane Library, PubMed, Google Scholar, and
44 EMBASE. We plan to include only randomized control clinical trials on GLP 1RA, fixed
45 ratio combination of basal insulin and GLP 1RA and basal insulins alone. A validated study
46 design-specific critical appraisal tool will be used to assess the risk of bias in individual
47 studies. The systematic review will be performed in accordance with the JBI guideline for
48 prevalence and incidence review. The review will be reporting following the Preferred
49 Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guideline.

50

51

52 **Introduction**

53 In patients with T2DM, blood glucose control is a major goal of management demonstrated by
54 many guidelines and results of clinical trials.(1–3) It has been reported in the literature that
55 micro and macro vascular risks increased with poor glycaemic control. The UKPDS for
56 instance found that improved control of blood glucose or blood pressure reduced the risk of
57 major diabetic eye disease by one quarter, serious deterioration of vision by nearly one half,
58 early kidney damage by one third, strokes by one third, and death from diabetes-related causes
59 by one third.(3)

60 Over the past few decades, the cardiovascular benefits and lower risks of hypoglycaemia of the
61 Glucagon like peptide 1 receptor agonists (GLP-1 RAs) has made them a major part of many
62 guidelines for the management of diabetes mellitus.(4,5) Basal insulins on the hand have been
63 shown to be highly effective in glycaemic control of patients with T2DM.(6) They reduce
64 fasting blood glucose levels and improve glycaemia but are associated with higher risks of
65 hypoglycaemia compared to the GLP-1 RAs.

66 Recently the potential benefit of using the combination of GLP-1 RAs and basal insulin in the
67 pharmacological treatment of type 2 diabetes mellitus has been shown to improve glyceemic
68 control. (7,8)

69 There are several combinations of GLP-1 RAs and basal insulins in fixed ratio combinations
70 available for use in a single injection pen currently available. (9)

71 The potential benefits of combining GLP-1RAs with basal insulin in fixed ratio combinations
72 is to Improve glycaemia, while reducing the risks of hypoglycaemia and lower the risks of
73 weight gain.(9)

74 This protocol intends to review the therapeutic efficacy, safety and cardiovascular benefit of
75 the fixed ratio combinations of the GLP-1 RAs and basal insulins in comparison with the GLP-
76 1 RAs alone or basal insulins alone.

77 **Aim and objectives**

78 This study aims to conduct a systematic review and meta-analysis of randomized controlled
79 clinical trials with the aim of evaluating the therapeutic efficacy of glucagon-like peptide-1
80 receptor agonists combined with basal insulin therapy in treating type 2 diabetes, using a fixed-
81 ratio combination of the two.

82 The secondary objectives of the systematic review will include:

83 1. to determine the cardiovascular outcome of a fixed-ratio combination of glucagon-like
84 peptide-1 receptor agonist versus basal insulin alone or in combination with prandial insulin
85 therapy for the treatment of type 2 diabetes

86 2. to determine the incidence of adverse events in patients with type 2 diabetes on a fixed-ratio
87 combination of glucagon-like peptide-1 receptor agonist versus basal insulin alone or in
88 combination with prandial insulin

89 3. to compare the effects of a fixed-ratio combination of glucagon-like peptide-1 receptor
90 agonist versus basal insulin alone or in combination with prandial insulin on weight and
91 hypoglycemia in patients with type 2 diabetes.

92 **Method**

93 **Registration and reporting of the review findings**

94 The protocol for this review has been registered with Prospero with the registration number
95 CRD42022363619. We will use PRISMA (Preferred Reporting Items for Systematic Reviews
96 and Meta-Analyses)(10) to report the findings of this study. In order to conduct this systematic
97 review, we will follow the guidelines set by the Joanna Briggs Institute (JBI) for systematic
98 reviews.(11)

99 **Study eligibility**

100 Population, intervention, comparison, and outcome (PICO) protocols will be used to evaluate
101 study eligibility.

102 Population – Randomized controlled trials conducted on adult T2DM patients.

103 Intervention - GLP-1RA and basal insulin, or GLP-1RA alone or basal insulin alone.

104 Comparison - T2DM patients using GLP-1RA and basal insulin will be compared to GLP-1RA
105 alone or basal insulin alone (comparator).

106 Outcome – Reduction in HbA1c from baseline, reduction in fasting plasma glucose levels,
107 hypoglycemia, and weight gain.

108 **Search strategy**

109 The Preferred Reporting Items for Systematic Reviews and Metanalyses checklist will be
110 utilized for the systematic review of the literature. Searches of the literature will be conducted
111 in the Cochrane Library, PubMed, Google Scholar, and EMBASE. The research will be
112 randomized control trials only. There will be no language restrictions on the studies and articles
113 selected for the review. The search strategy will include terms for GLP 1 agonists and basal
114 insulin fixed-dose combination, GLP 1 agonists, basal insulin, basal-bolus insulin, prandial

115 insulin, cardiovascular benefits, adverse events, hypoglycemia, weight reduction, efficacy, and
116 adherence.

117 **Population characteristics**

118 (1) Patients with type 2 diabetes who were initiated on the fixed ratio combination or switched
119 to the fixed ratio combination for at least 12 weeks

120 (2) Patients with type 2 diabetes either initiated on basal insulin or prandial insulin with or
121 without basal insulin or switched to basal insulin or prandial insulin with or without basal
122 insulin for at least 12 weeks

123 (3) Outcome measures: therapeutic efficacy, cardiovascular outcome, adverse events and
124 effects on weight.

125 Basal insulin or prandial insulin with or without basal insulin or switched to basal insulin or
126 prandial insulin with or without basal insulin for at least 12 weeks

127 (4) Secondary outcome measures: Therapeutic efficacy, cardiovascular outcome, adverse
128 events and effects on weight

129 **Research question**

130 What is the therapeutic efficacy of GLP1 agonist and basal insulin fixed-dose combinations in
131 the treatment of type 2 diabetes compared to GLP1 agonists or basal insulin alone?

132 What is the cardiovascular benefit of using GLP1 agonist and basal insulin fixed-dose
133 combinations in the treatment of type 2 diabetes compared to GLP1 agonists or basal insulin
134 alone?

135 What is the burden of adverse effects of GLP1 agonist and basal insulin fixed-dose
136 combinations in the treatment of type 2 diabetes compared to GLP1 agonists or basal insulin
137 alone?

138 **Eligibility criteria**

139 **Inclusion criteria:**

140 Randomized controlled clinical trials that provide estimates of efficacy, adverse events or
141 cardiovascular outcomes and effects on weight.

142 Outcome index: therapeutic efficacy, cardiovascular outcome, adverse events and effects on
143 weight.

144 **Exclusion criteria:**

145 Qualitative studies, case reports, case series, case-control studies, conference proceedings,
146 prospective and retrospective observational studies, descriptive and analytical cross-sectional
147 studies. Expert opinions, and randomized control trials not reporting estimates of therapeutic
148 efficacy, unpublished data, repeated publication of literature, or where the full text is not
149 available. Or where the data cannot be extracted.

150 **Language**

151 Only studies written in English or with an available English version, or with the possibility of
152 translating the full article via Google Translate, will be included.

153 **Study period**

154 We will focus on the past three decades; therefore, we will include studies conducted from
155 1st January 1990 to 30th of June 2023.

156 **Electronic searches**

157 It is anticipated that the following electronic databases will be searched: The Cochrane Library,
158 PubMed, Google Scholar, and EMBASE. The research will be randomized control trials only.
159 There will be no language restrictions on studies and articles selected for the review. The search
160 strategy will include terms for GLP 1 agonists and basal insulin fixed-dose combination, GLP
161 1 agonists, basal insulin, basal-bolus insulin, prandial insulin, cardiovascular benefits, adverse
162 events, hypoglycemia, weight reduction, efficacy, and adherence. (See S1 Appendix). Terms
163 representing similar concepts will be separated using the Boolean operator “OR” while terms
164 representing different concepts will be separated using the Boolean operator “AND”. Where
165 the full text of relevant studies cannot be retrieved, efforts will be made to request the full text
166 from study corresponding authors.

167 The literature will be independently screened by 2 researchers to identify articles that meet the
168 inclusion criteria. Firstly, according to the weight of the topic, review the topic summary to
169 exclude irrelevant literature. Then read the full text to select literature according to the inclusion
170 and exclusion criteria. Finally, two people will check the results, and if their opinions don't
171 agree, a third party will take the decision. The following contents will be extracted from the
172 included literature: first author, year of publication, age of study subjects, study site, estimates
173 of efficacy, adverse events, effects of weight and hypoglycaemia. The reasons for the exclusion
174 of full-text articles will be given. PRISMA flow diagrams will be used to describe and
175 summarize the search results and selection process. A table will be used to report the details of
176 all the included studies.

177 **Other searches**

178 A hand search will be conducted for unpublished studies/grey literature using the keywords
179 found in the study through Google Scholar and gray literature databases such as WHO Library,
180 OpenSIGLE, and Open Gray.

181 **Risk of bias**

182 The risk of bias in the included studies will be assessed using the Joanna Briggs Institute (JBI)
183 tool. We will describe any assessment of the risk of bias that may affect the cumulative
184 evidence (e.g., publication bias, selective reporting within studies).

185 **Data extraction**

186 The primary changes in HbA1c from baseline to the end of treatment. Changes in the levels of
187 fasting plasma glucose from baseline to the end of the study, changes in the body weights of
188 the participants and the proportion of participants reaching the HbA1c target <7.0% at the end
189 of the study. Reported and documented hypoglycaemic episodes during the period of treatment.

190 **Strategy for data synthesis**

191 A quantitative meta-analysis will be performed on the estimates of efficacy, adverse events,
192 effects of weight and hypoglycaemia in patients with type 2 diabetes using Stata17.0. Pooled
193 estimates of weighted means differences (WMDS) and 95% CI for continuous outcomes;
194 changes in HbA1c, FPG, as well as the pooled risk ratios (RR) of dichotomous outcomes
195 including the proportion of participants achieving HbA1c target values and the risks of
196 hypoglycaemia will be calculated.

197 Heterogeneity will be assessed using the I^2 statistic for each analysis, with the significance
198 level set at $P < 0.05$. If there is found to be significant heterogeneity between the studies, the
199 random effects model will be used, or these studies will be divided into specific subgroups,

200 based on different factors. The potential risks of publication bias will be evaluated by
201 constructing funnel plots of primary outcomes with asymmetry assessed by Egger's test.

202 A forest plot will be used to illustrate the distribution of the outcome and effect sizes obtained
203 from each published study. In addition, publication bias will also be assessed, and a sensitivity
204 analysis carried out.

205 **Analysis of subgroups or subsets**

206 A sensitivity analysis comparing the intervention arm GLP-1 agonist and basal insulin with
207 basal insulin therapy or basal-bolus insulin is planned. Subgroup analysis will also be
208 conducted. The efficacy of individual FRC drugs will be reported using a forest plot.

209 **Assessment of certainty of evidence**

210 To assess the quality of the synthesised findings, we will use the GRADE instrument and
211 Gradepro Software. Studies included in the analysis will be assessed for their design,
212 heterogeneity, consistency, directness, precision, and publication bias. A quality rating will be
213 assigned to the evidence: high, moderate, low or very low.

214 **Discussion**

215 The proposed study will provide the first insight into the comparative efficacy, safety, and
216 adverse effects profile of the fixed ration combination of GLP-1RA and basal insulin in
217 comparison to basal insulin alone or GLP1-RA alone. Also, the specific cardiovascular benefit
218 of the fixed ration combination of the GLP-1 receptor agonist with basal insulin has not been
219 completely elucidated although the cardiovascular benefit of GLP-1 RA has been well
220 established.(9) The fixed-ratio combination of GLP1 RA and basal insulin is relatively new but
221 in previous studies that compared with the basal-bolus insulin regimen, the combination of

222 GLP-1RA and basal insulin displayed a similar benefit in lowering HbA1c with a 33% lower
223 risk of hypoglycemia and 5.66 kg less body weight gain.(12)

224 The combination of basal insulin GLP -1 RA is a synergistic effect that is produced by the
225 activity of the basal insulin principally suppressing fasting plasma glucose, and the GLP 1 RA
226 that acts by suppressing the postprandial glucose excursions.

227

228 We expect that the study will be conducted using a systematic approach utilizing a well-defined
229 protocol and following a standard algorithm for data collection and analysis. Among the
230 potential limitations, heterogeneity in individual studies may be encountered due to the quality
231 of the study designs, definitions used, or evaluation methods. A detailed narrative report will,
232 however, be provided highlighting these discrepancies and providing suggestions for
233 improving future research.

234 **Acknowledgments**

235 Nil

236 **References**

- 237 1. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin
238 therapy prevents the progression of diabetic microvascular complications in Japanese
239 patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-
240 year study. *Diabetes Res Clin Pract.* 1995 May;28(2):103–17.
- 241 2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of
242 Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine.* 2008
243 Oct 9;359(15):1577–89.
- 244 3. Leslie RDG. United Kingdom Prospective Diabetes Study (UKPDS): what now or so
245 what? *Diabetes Metab Res Rev.* 1999 Jan;15(1):65–71.
- 246 4. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the
247 Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
248 *Circulation.* 2022 Dec 13;146(24):1882–94.
- 249 5. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent
250 cardiovascular outcomes trials. *Postgrad Med J.* 2020 Mar 1;96(1133):156–61.
- 251 6. Hedrington MS, Pulliam L, Davis SN. Basal Insulin Treatment in Type 2 Diabetes.
252 *Diabetes Technol Ther.* 2011 Jun;13(S1):S-33-S-42.

- 253 7. Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1
254 receptor agonist: is this the end of basal insulin alone in the treatment of type 2
255 diabetes? *Diabetol Metab Syndr*. 2018 Dec 3;10(1):26.
- 256 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in
257 Diabetes—2021. *Diabetes Care*. 2021 Jan 1;44(Supplement_1):S111–24.
- 258 9. Lisco G, de Tullio A, Guastamacchia E, Triggiani V. Fixed-Ratio Combinations of Basal
259 Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from
260 the Literature. *Endocr Metab Immune Disord Drug Targets*. 2021 Apr;21(4):626–46.
- 261 10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
262 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst
263 Rev*. 2021 Dec 29;10(1):89.
- 264 11. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Systematic reviews of prevalence and
265 incidence. Joanna Briggs Institute reviewer’s manual Adelaide, South Australia: The
266 Joanna Briggs Institute. 2017:5–1.
- 267 12. Jung HN, Cho YK, Min SH, Kim HS, Kim YJ, Park JY, et al. Free Versus Fixed-Ratio
268 Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes
269 Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect
270 Treatment Comparison. *Front Endocrinol (Lausanne)*. 2022 May 20;13.
271
- 272 Source of funding - Self funded
- 273 Supporting information
- 274 Appendix 1
- 275 PRISMA Check list
- 276